Sutro Biopharma Set to Reveal Q4 2025 Earnings on March 12

Sutro Biopharma (NASDAQ:STRO) is poised to announce its financial results for the fourth quarter of 2025 on March 12, 2025, prior to the market opening. Analysts forecast that the company will report a loss of ($4.66) per share alongside revenues of approximately $9.263 million for the quarter. Investors and interested parties can access details about the earnings conference call scheduled for March 27, 2026, at 16:00 ET on the company’s official webpage.

Sutro Biopharma Stock Overview

As of Tuesday, Sutro Biopharma shares opened at $24.98. The company boasts a market capitalization of $212.58 million with a price-to-earnings (P/E) ratio of -0.96 and a beta of 1.47. Over the past year, the stock has shown significant volatility, with a low of $5.23 and a high of $26.54. The fifty-day moving average stands at $15.86, while the 200-day moving average is at $11.62.

A variety of analysts have weighed in on Sutro Biopharma shares, with recommendations reflecting differing outlooks. On December 2, 2025, Wedbush maintained a “neutral” rating, increasing its price target to $100.00 from $20.00. Following this, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on December 17, 2025. Later, HC Wainwright adjusted its price target to $10.00 while keeping a “neutral” rating as of December 22, 2025. Citigroup also upgraded the stock to an “outperform” rating on January 20, 2026.

Currently, the consensus among analysts indicates that four have rated the stock as a buy, three as hold, and two as sell. According to data from MarketBeat, Sutro Biopharma has an average rating of “Hold” with a consensus target price of $31.83.

Institutional Investments in Sutro Biopharma

Recent activity from hedge funds shows a notable interest in Sutro Biopharma. Velan Capital Investment Management LP increased its stake by 2.0%, owning 3,120,000 shares valued at $2.709 million after acquiring an additional 60,000 shares in the last quarter. Similarly, UBS Group AG raised its stake by 14.0%, owning 1,845,839 shares worth $1.602 million after purchasing 226,955 shares recently.

AQR Capital Management LLC exhibited a significant increase, boosting its holdings by 1,052.8% to own 1,320,917 shares, valued at $859,000. Other notable investments include Jane Street Group LLC, which bought a new position valued at approximately $492,000, and Jacobs Levy Equity Management Inc., acquiring a stake worth around $387,000. Hedge funds and institutional investors collectively own 96.99% of Sutro Biopharma’s stock.

Sutro Biopharma, based in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative biologic drug candidates in oncology and immunology. Utilizing its proprietary cell-free protein synthesis platform, XpressCFTM, the company aims to produce complex proteins, such as antibody-drug conjugates and bispecific antibodies. Founded in 2003, Sutro Biopharma is advancing a pipeline of immuno-oncology candidates at various stages of development.

For those looking to stay updated on Sutro Biopharma, a daily summary of news and analysts’ ratings can be received through MarketBeat’s free newsletter.